eprintid: 20651
rev_number: 20
userid: 1419
dir: disk0/00/02/06/51
datestamp: 2014-07-01 17:20:22
lastmod: 2019-02-04 23:55:04
status_changed: 2014-07-01 17:20:22
type: article
metadata_visibility: show
item_issues_count: 0
eprint_status: archive
creators_name: Braunstein, MJ
creators_name: Scott, SS
creators_name: Scott, CM
creators_name: Behrman, S
creators_name: Walter, P
creators_name: Wipf, P
creators_name: Coplan, JD
creators_name: Chrico, W
creators_name: Joseph, D
creators_name: Brodsky, JL
creators_name: Batuman, O
creators_email: 
creators_email: 
creators_email: 
creators_email: 
creators_email: 
creators_email: pwipf@pitt.edu
creators_email: 
creators_email: 
creators_email: 
creators_email: jbrodsky@pitt.edu
creators_email: 
creators_id: 
creators_id: 
creators_id: 
creators_id: 
creators_id: 
creators_id: PWIPF
creators_id: 
creators_id: 
creators_id: 
creators_id: JBRODSKY
creators_id: 
creators_orcid: 
creators_orcid: 
creators_orcid: 
creators_orcid: 
creators_orcid: 
creators_orcid: 
creators_orcid: 
creators_orcid: 
creators_orcid: 
creators_orcid: 0000-0002-6984-8486
creators_orcid: 
title: Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101
ispublished: pub
divisions: sch_as_chemistry
full_text_status: public
abstract: Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable, primarily due to the treatment-refractory/resistant nature of the disease. A rational approach to this compelling challenge is to develop new drugs that act synergistically with existing effective agents. This approach will reduce drug concentrations, avoid treatment resistance, and also improve treatment effectiveness by targeting new and nonredundant pathways in MM. Toward this goal, we examined the antimyeloma effects of MAL3-101, a member of a new class of non-ATP-site inhibitors of the heat shock protein (Hsp) 70 molecular chaperone. We discovered that MAL3-101 exhibited antimyeloma effects on MM cell lines in vitro and in vivo in a xenograft plasmacytoma model, as well as on primary tumor cells and bone marrow endothelial cells from myeloma patients. In combination with a proteasome inhibitor, MAL3-101 significantly potentiated the in vitro and in vivo antimyeloma effects. These data support a preclinical rationale for small molecule inhibition of Hsp70 function, either alone or in combination with other agents, as an effective therapeutic strategy for MM. Copyright © 2011 Marc J. Braunstein et al.
date: 2011-11-24
date_type: published
publication: Journal of Oncology
refereed: TRUE
issn: 1687-8450
id_number: 10.1155/2011/232037
other_id: NLM PMC3184436
pmcid: PMC3184436
pmid: 21977030
citation:   Braunstein, MJ and Scott, SS and Scott, CM and Behrman, S and Walter, P and Wipf, P and Coplan, JD and Chrico, W and Joseph, D and Brodsky, JL and Batuman, O  (2011) Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101.  Journal of Oncology.   ISSN 1687-8450     
document_url: http://d-scholarship-dev.library.pitt.edu/20651/1/licence.txt